Regulatory milestones

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) lost $2.74 to $94.68 last week after announcing the U.K. Ministers of Health deferred a decision to cover Soliris eculizumab on the NHS for atypical hemolytic uremic syndrome (aHUS). According to the company, the ministers overruled a positive recommendation to cover the drug from the Advisory Group for National Specialised Services (AGNSS), which was tasked with assessing high-cost drugs for rare conditions. AGNSS was disbanded last year.